Myelofibrosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Myelofibrosis is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Symptoms include severe anemia, weakness, fatigue, and splenomegaly. The JAK inhibitors ruxolitinib (Incyte), fedratinib (Bristol Myers Squibb), pacritinib (CTI BioPharma), and momelotinib (GSK) are the only drugs approved for myelofibrosis in the United States and EU5 (pacritinib only in the United States). Although JAK inhibitors are a therapeutic option, they do not address all myelofibrosis symptoms and are associated with high discontinuation rates. Thus, significant market opportunity remains for safe and tolerable treatments that can manage the full spectrum of myelofibrosis symptoms (reducing the need for polypharmacy) and that can treat patients with comorbid thrombocytopenia and anemia.
Questions answered
- What are the sizes of the U.S. and EU5 diagnosed prevalent and incident primary and secondary myelofibrosis populations? What are the distributions of risk level among diagnosed incident and prevalent cases of primary myelofibrosis?
- What is the current treatment landscape for myelofibrosis? What are physicians’ experience and satisfaction with current key therapies?
- How have ruxolitinib, fedratinib, pacritinib, and momelotinib been integrated into the myelofibrosis treatment algorithm? How will these drugs compete in the treatment of myelofibrosis?
- What are the key unmet needs and areas of commercial opportunity for myelofibrosis? How will novel therapies impact the treatment algorithm for myelofibrosis, and which myelofibrosis patients will be served by these treatment options in 2033?
Geography: United States and EU5.
Primary research: Five country-specific interviews with thought-leading hematologists. Supported by survey data collected for this study.
Epidemiology: Diagnosed incidence and prevalence of primary and secondary myelofibrosis by country, diagnosed incidence and prevalence of primary myelofibrosis by risk (DIPSS and IPSS, respectively), comorbidities, and biomarkers (JAK2 mutation, peripheral blasts > 1%, splenomegaly), with population-specific drug-treatment rates.
Forecast: Drug-level sales and patient share of key myelofibrosis therapies in 2023 and 2033.
Drug treatments: Coverage of key current and emerging therapies.
Product description: Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
Key feature: Niche & Rare Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations
Table of contents
- Myelofibrosis - Landscape & Forecast - Niche & Rare Disease Landscape & Forecast (US/EU5)
- Content announcement
- Executive Summary
- Commercial Outlook and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class-specific trends
- Forecast
- Sales of key therapies in myelofibrosis: 2023 and 2033
- Patient shares of key therapies in lower-risk myelofibrosis: 2023 and 2033
- Patient shares of key therapies in intermediate-1-risk myelofibrosis: 2023 and 2033
- Patient shares of key therapies in intermediate-2-risk myelofibrosis: 2023 and 2033
- Patient shares of key therapies in high-risk myelofibrosis: 2023 and 2033
- Alternative market scenarios for the myelofibrosis market through 2033
- Key takeaways
- Disease Context
- Epidemiology
- Key takeaways
- Diagnosed incident cases of myelofibrosis
- Diagnosed prevalent cases of myelofibrosis
- Diagnosed incident cases of primary myelofibrosis
- Diagnosed prevalent cases of primary myelofibrosis
- Diagnosed incident cases of secondary myelofibrosis
- Diagnosed prevalent cases of secondary myelofibrosis
- Diagnosed incident cases of myelofibrosis by IPSS risk group
- Diagnosed prevalent cases of myelofibrosis by DIPSS risk group
- Diagnosed incident cases of primary myelofibrosis by comorbidity
- Diagnosed prevalent cases of primary myelofibrosis by comorbidity
- Diagnosed incident cases of primary myelofibrosis by biomarker status
- Diagnosed prevalent cases of primary myelofibrosis by biomarker status
- Diagnosed incident cases of secondary myelofibrosis by MYSEC-PM risk group
- Diagnosed and drug-treated populations
- Key takeaways
- Current Treatment
- Emerging Therapies
- Drug Pipeline
- Methodology
- Bottom-up forecasting overview
- Bottom-up forecast key events and assumptions
- Market events impacting the myelofibrosis forecast
- Drug-treatment rate assumptions in myelofibrosis
- Forecast market authorization dates of key emerging therapies for the treatment of myelofibrosis
- Generic erosion
- Generic erosion assumptions
- Dosing assumptions of key therapies in myelofibrosis
- Days of therapy and compliance
- Emerging therapy prices
- Prices of key current and emerging therapies used to treat myelofibrosis
- Bottom-up forecast methodology
- Primary market research
- Appendix
